# About PT-141 Dr: An Editorial Digest of the Bremelanotide Record

> PT-141 Dr is an independent editorial project that summarizes the peer-reviewed research and the approved label for PT-141 (bremelanotide). Not a clinic. Not a vendor.

An independent editorial reading of the bremelanotide literature — the data and the caveats, stated plainly.

## What this site is

PT-141 Dr is an independent editorial project that publishes summaries of the peer-reviewed research literature on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and the approved drug label.

The register here is deliberately cold and plain. PT-141's honest record is uncomfortable: one narrow approved indication, a short half-life, a firm label dose, and a tolerability ceiling — a transient blood-pressure rise, common nausea, hyperpigmentation with repeated dosing, a disputed older study, and a published argument that the trial benefits are small. We state the data and the caveats without ornament.

## The 'Dr' is a reading posture, not a clinic

The "Dr" in the domain is editorial framing. It marks a posture toward the literature — a grave, exacting reader of the evidence — not a claim about services. There is no physician here, no clinical team, no consultation, no prescription, and no dispensing. We will not tell you to take anything.

Every dose and figure on this site is reported as a study finding or a label specification, attributed to a source, and never offered as personal guidance. Where the evidence is precise — the ~2.7 hour half-life, the 1.75 mg approved dose — we say so. Where it is contested — the magnitude of the desire benefit — we report the critique alongside the result.

## How we handle the evidence

Two layers, kept apart. The first is cited clinical evidence: efficacy endpoints and the adverse-event profile drawn straight from the randomized trials, the long-term extension, and the US prescribing information, with every quantitative claim mapped to a numbered reference. The second is a clearly labeled field-reports layer — commonly described first-hand accounts from public discussion, marked unverified, attributed to no journal, and walled off from the cited record so an anecdote can never be mistaken for a finding.

Where the published record disagrees with itself, we keep the disagreement visible. The approval is real; so is the published argument that the trial benefit is small; so is the disputed status of one older male study. We report all three rather than smoothing them into a single tidy line.

We avoid brand names entirely, use only international nonproprietary names, and make no claim that PT-141 treats or cures anything beyond stating its single approved indication. The references page lists everything we cite, and any correction that improves accuracy is welcome.

---

A cold reading of the bremelanotide record — the trial numbers, the label warnings, and the field reports walled off as unverified; no clinic in the dark behind it, and nothing here dispensed, priced, or sold.